ProteoGenix antibody library to help fight COVID-19
ProteoGenix, a global leader in antibody production based in France, has announced its Human Immune COVID-19 library for the fast discovery of potent antibodies against SARS-CoV-2 — claimed to be a world first.
“Highly sensitive and specific antibodies are critical for the development of diagnostics, therapeutics and prophylactics to fight against COVID-19,” said ProteoGenix President and co-founder Philippe Funfrock. “The new Human Immune COVID-19 antibody library developed by ProteoGenix represents an exciting opportunity to solve the current pandemic.”
The library, created using blood samples from dozens of recovered COVID-19 patients, is adapted for screening with phage display and strives to meet the rising demands for effective antibodies for a broad range of applications.
The library’s vast diversity (1.2 x 1010 different clones), allied to the fast turnaround time and sensitivity of the screening technology, is intended to fast-track the discovery of antibodies with the strongest affinity, specificity and viral blocking activity.
“Compared to the hybridoma technology, phage display saves time by allowing us to directly screen highly diverse and human antibody libraries,” said ProteoGenix CSO and co-founder Raphaël Hopfner. “In addition, when developing therapeutic antibodies, this technique also helps us reduce the time to market by avoiding complex antibody humanisation processes.”
ProteoGenix further fast-tracks the process of discovery by offering a broad diversity of ready-made SARS-CoV-2 antigens, as well as fast custom antigen development services (proteins, peptides, small molecules).
Within eight weeks or less, clients can receive 3–10 royalty-free antibody sequences with an optimal affinity. ProteoGenix aims to use this service to support the efforts of teams fighting the COVID-19 pandemic around the world.
Researchers have used a portable analyser to detect anti-avian influenza virus antibody in blood...
The reagents have a simple structural composition that can simultaneously target and modulate...
COVID-19 Immunoglobulin will be developed using donations of plasma made in Australia by people...